European Union executive signs remdesivir deal with Gilead

European Union executive signs remdesivir deal with Gilead
European Union executive signs remdesivir deal with Gilead Spinant said the contract was worth 63 million euros ($73.99 million) and would provide treatment to 30,000 patients with severe COVID-19 symptoms.